JOURNAL BROWSE
Search
Advanced SearchSearch Tips
CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients
Yazdi, Mohammad Forat; Rafieian, Shiva; Gholi-Nataj, Mohsen; Sheikhha, Mohammad Hasan; Nazari, Tahereh; Neamatzadeh, Hossein;
  PDF(new window)
 Abstract
Background: Despite consistent pharmacogenetic effects of CYP2D6 on tamoxifen exposure, there is considerable controversy regarding the validity of CYP2D6 as a predictor of tamoxifen outcome. Understanding the current state of evidence in this area and its limitations is important for the care of patients who require endocrine therapy for breast cancer. Materials and Methods: A total of 101 patients with breast cancer who received tamoxifen therapy for at least 3 years, were genotyped for common alleles of the CYP2D6 gene by nested-PCR and restriction fragment length polymorphism PCR. Patients were classified as extensive or poor metabolizers (PM) based on CYP2D6*4 alleles in 3 different groups according to the menopause, Her2-neu status, and stage 3. Results: The mean age of the patients with the disease recurrence was and in non recurrent patients was . In this study 63.3% (n
 Keywords
Breast cancer;tamoxifen;recurrent;menopause;CYP2D6;
 Language
English
 Cited by
 References
1.
Abraham JE, Maranian MJ, Driver KE, et al (2010). CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res, 12, 64.

2.
Bijl MJ, van Schaik RH, Lammers LA, et al (2009). The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat, 118, 125-30. crossref(new window)

3.
Brauch H, Schroth W, Eichelbaum M, et al (2008). Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer. Breast Care, 3, 43-50. crossref(new window)

4.
Darakhshan S, Bidmeshkipour A, Khazaei M, et al (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP 9 regulation in cultured human breastcancer cells. Asian Pac J Cancer Prev, 14, 6869-74. crossref(new window)

5.
Dowsett M, Procter M, McCaskill-Stevens W, et al (2009). Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol, 27, 2962-9. crossref(new window)

6.
Hassan BA, Yusoff ZB (2011). Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 12, 185-91.

7.
Hayes DF, Stearns V, Rae J, Flockhart D (2008). A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst, 100, 610-3. crossref(new window)

8.
Goetz MP, Rae JM, Suman VJ, et al (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol, 23, 9312-8. crossref(new window)

9.
Goetz MP, Kamal A, Ames MM (2008). Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther. 83, 160-6. crossref(new window)

10.
Gonzalez-Santiago S, Zarate R, Haba-Rodriguez J, et al (2007). CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. J Clin Oncol, 18, 590.

11.
Forat-Yazdi M, Neamatzadeh H, Sheikhha MH, Zare-Shehneh M, Fattahi M (2015). BRCA1 and BRCA2 common mutations in iranian breast cancer patients: a meta analysis. Asian Pac J Cancer Prev, 16, 1219-24. crossref(new window)

12.
Jin TB, Ma LF, Zhang JY, et al (2013). Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population. Gene, 527, 360-5. crossref(new window)

13.
Kirchheiner J, Schmidt H, Tzvetkov M, et al (2007). Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J, 7, 257-65. crossref(new window)

14.
Lash TL, Cronin-Fenton D, Ahern TP, et al (2011). CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst, 103, 489-500. crossref(new window)

15.
Martinez de Duenas E, Ochoa Aranda E, Blancas Lopez-Barajas I, et al (2014). Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype. Breast, 23, 400-6. crossref(new window)

16.
Morrow PK, Serna R, Broglio K, et al (2012). Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer, 118, 1221-7. crossref(new window)

17.
Martins DM, Vidal FC, Souza RD, et al (2014). Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in Sao Luis, Brazil, and itsassociation with prognostic factors and disease-free survival. Braz J Med Biol Res, 47, 1008-15. crossref(new window)

18.
Meiyanto E, Hermawan A, Anindyajati (2012). Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev, 13, 427-36. crossref(new window)

19.
Motamedi S, Majidzadeh K, Mazaheri M, et al (2012). Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients. Asian Pac J Cancer Prev, 13, 6101-4. crossref(new window)

20.
Nelson R (2012). CYP2D6 has impact on effectiveness of tamoxifen. medscape medical news. Available at: http://www.medscape.com/viewarticle/776933

21.
Nowell SA, Ahn J, Rae JM, et al (2005). Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat, 91, 249-58. crossref(new window)

22.
Okishiro M, Taguchi T, Jin Kim S, et al (2009). Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer, 115, 952-61. crossref(new window)

23.
Park IH, Ro J, Park S, et al (2013). Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat, 131, 455-61.

24.
Serin A, Canan H, Alper B, Gulmen M (2012). The frequencies of mutated alleles of CYP2D6 gene in a Turkish population. Forensic Sci Int, 222, 332-4. crossref(new window)

25.
Schorth W, Antoniadou L, Fritz P, et al (2007). Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol, 25, 5187-93. crossref(new window)

26.
Schroth W, Goetz MP, Hamann U, et al (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 302, 1429-36. crossref(new window)

27.
Shiryazdi SM, Kargar S, Taheri-Nasaj H, Neamatzadeh H (2015). BreastLight apparatus performance in detection of breast masses depends on mass size. Asian Pac J Cancer Prev, 16, 1181-4. crossref(new window)

28.
Sukasem C, Sirachainan E, Chamnanphon M, et al (2012). Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-basedstudy in Thailand. Asian Pac J Cancer Prev, 13, 4549-53. crossref(new window)

29.
Wegman P, Elingarami S, Carstensen J, et al (2007). Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res, 9, 7.

30.
Wegman P, Vainikka L, Stal O, et al (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res, 7, 284-290. crossref(new window)

31.
Zhou LP, Luan H, Dong XH, et al (2012). Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 3165-72. crossref(new window)